MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Salmi Abdul Razak; Mohd Makmor-bakry; Adyani Md Redzuan

doi:10.22159/ajpcr.2018.v11i11.27953

Authors

Salmi Abdul Razak Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Federal Territory of Kuala Lumpur.
Mohd Makmor-bakry Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Federal Territory of Kuala Lumpur.
Adyani Md Redzuan Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Federal Territory of Kuala Lumpur.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i11.27953

Keywords:

Biologic therapy, Non-tumor necrosis factor inhibitors, Precaution, Prescreening, Rheumatoid arthritis, Tumor necrosis factor inhibitor

Abstract

Rheumatoid arthritis (RA) is a progressive chronic inflammatory disease affecting 0.5â€“1.0% of the adult population worldwide. Due to the damages caused by this autoimmune disease, new biologic therapies, particularly the biologic disease-modifying antirheumatic drugs (bDMARDs), are now being the treatment of choice in the management of RA. However, special precaution and prescreening before the usage of bDMARDs are needed to ensure better clinical response and avoiding risk of adverse event during treatment with the selected bDMARDs. In this review paper, we will provide overview on the incidence and pathogenesis of the disease, available pharmacological treatment and emphasizing special consideration in need on initiation of bDMARDs among RA patients. A literature review was performed by searching for relevant articles in Medline database through PubMed using medical subject headings terms and keywords: RA, bDMARDs, special consideration, tumor necrosis factor inhibitor, and non-tumor necrosis factor inhibitor. All papers reviewed were from 1999 to 2017 and were written in English. In this article, use of conventional synthetic DMARDs (csDMARDs), bDMARDs and special consideration to be taken upon initiation of biologic therapies in RA will be reviewed.

Downloads

Download data is not yet available.

References

Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.

Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6.

Jalil SF, Arshad M, Bhatti A, Ahmad J, Akbar F, Ali S, et al. Rheumatoid arthritis: What have we learned about the causing factors? Pak J Pharm Sci 2016;29:629-45.

Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology 2012;51 Suppl 6:vi28-36.

Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.

Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. Recommendations for the management of polymyalgia rheumatica: A European league against rheumatism/American college of rheumatology collaborative initiative. Arthritis Rheumatol 2015;67:2569-80.

RomÃ£o VC, Vital EM, Fonseca JE, Buch MH. Right drug, right patient, right time: Aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther 2017;19:239.

Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82.

Minichiello E, Semerano L, Boissier MC. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Jt Bone Spine 2016;83:625-30.

Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18:S295-302.

Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4 Suppl 3:S265-72.

Doran MF, Pond GR, Crowson CS, Oâ€™Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in rochester, minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.

Choy E. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012;51 Suppl 5:v3 11.

Mielants H, Van Den BF. Extra-articular manifestations. Clin Exp Rheumatol 2009;27 Suppl 55:S56-61.

Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008;24:469-80.

Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004;33:65- 72.

Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: Quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23 5 Suppl 39:S43-52.

Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, Oâ€™Fallon WM, et al. Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.

Turesson C, Oâ€™Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: Incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62:722-7.

Vela P. Extra-articular manifestations of rheumatoid arthritis, now. Eur Med J Rheumatol 2014;1:103-12.

Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2013;73:62-8.

Turesson C, Jacobsson L, BergstrÃ¶m U. Extra-articular rheumatoid arthritis: Prevalence and mortality. Rheumatology 1999;38:668-74.

Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in ra and their impact on outcome. Rheumatol (United Kingdom) 2013;52:99-110.

Smolen JS, LandewÃ© R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.

van Vollenhoven RF. Treatment of rheumatoid arthritis: State of the art 2009. Nat Rev Rheumatol 2009;5:531-41.

Wilske KR. Inverting the therapeutic pyramid: Observations and recommendations on new directions in rheumatoid arthritis therapy based on the authorâ€™s experience. Semin Arthritis Rheum 1993;23:11-8.

Oâ€™Dell JR. Treating rheumatoid arthritis early: A window of opportunity? Arthritis Rheum 2002;46:283-5.

Jones G, Nash P, Hall S. Advances in rheumatoid arthritis. Med J Aust 2017;206:221-4.

Wee AS, Shahrir M, Redzuan AM. Medication adherence status among rheumatoid arthritis patients. Int J Pharm Pharm Sci 2016;8:3-7.

Wilske KR. Remodeling the therapeutic pyramid: Evolving therapeutic strategies for rheumatoid arthritis. Jpn J Rheumatol 1999;9:1-16.

van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, et al. Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation Utrecht, the Netherlands. Ann Rheum Dis 2000;59:468-77.

Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford) 2014;53:1742-51.

Singh JA, Saag KG, Bridges SLJ, Akl EA, Bannuru RR, Sullivan MC, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1-25.

Saeid K, Min LS, Surulivelrajan M, Girish TP. Demographic, clinical characteristics and drug prescription pattern in patients with rheumatoid arthritis in South Indian Tertiary care hospital. Int J Pharm Pharm Sci 2016;8:251-7.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. Update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA Intern Med 2011;305:1460-8.

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (United Kingdom) 2014;53:213- 22.

Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab Plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study. Arthritis Rheumatol 2015;67:1424-37.

Chaabo K, Kirkham B. Rheumatoid arthritis - Anti-TNF. Int Immunopharmacol 2015;27:180-4.

Bachmann F, Nast A, Sterry W, Philipp S. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg 2010;29:35- 47.

Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - Past, present and future. Cytokine Growth Factor Rev 2014;25:453-72.

van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.

Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British society for rheumatology biologics register. Arthritis Rheum 2006;54:2368-76.

Rychly DJ, Pharm D, Dipiro JT, Pharm D. Infections associated with tumor necrosis factor-Î± antagonists. Pharmacotherapy 2005;25:1181- 92.

Ramos S, Noqueira A, Dias A, GonÃ§alves A, Gaio A, Duarte R. Tuberculosis screening in patients receiving biological therapy. Acta Reumatol Port 2015;40:234-40.

Elandt K, Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011;13:223.

Askling J. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.

Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.

De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: The infection perspective. Curr Rheumatol Rev 2011;7:77-87.

Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012;59:1-12.

Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-5.

Lecluse LL, Piskin G, Mekkes JR, Bos JD, De Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008;159:527-36.

Lipsky PE, van der Heijde DM, Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.

Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: Systematic review. J Crohns Colitis 2015;9:806-15.

Anderson PJ. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34 5 Suppl:19-22.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One 2017;12:1-17.